ライフサイエンスコーパス: interleukin-6

1 e synthase, tumor necrosis factor-alpha, and interleukin 6).

2 e synthase, tumor necrosis factor-alpha, and interleukin 6).

3 aB target genes matrix metalloprotease 9 and interleukin 6.

4 STAT3 phosphorylation by tobacco extract or interleukin 6.

5 ion of XBP1, and that this activity requires interleukin 6.

6 y weight, and elevated levels of circulating interleukin 6.

7 nary hypertension in rats (n=8) and elevated interleukin 6.

8 H17 cell differentiation by cooperating with interleukin-6.

9 in the production of the pathogenic cytokine interleukin-6.

10 pared with survivors was only found for lung interleukin-6.

11 olate, vitamin B-12, C-reactive protein, and interleukin-6.

12 tion, which is associated with cyclin B1 and interleukin-6.

13 ition of exogenous Th17-promoting cytokines (interleukin 6, 1beta, and 23 and transforming growth fac

14 (median 6.0 mg/L vs 4.2 mg/L; p<0.0001) and interleukin 6 (3.2 vs 2.6 ng/L; p<0.0001) were significa

15 is was associated with greater inflammation (interleukin 6: 38% +/- 24% increase; P < 0.05; tumor nec

16 (63/82), hypoalbuminaemia (57/63), elevated interleukin 6 (57/63), hepatomegaly or splenomegaly (52/

17 47.8 vs 31 895.3 +/- 5916.5 pg/mL, P = .01), interleukin-6 (63.8 +/- 20.2 vs 111.5 +/- 29.6 pg/mL, P

18 erleukin-8: 70.75 vs 27.86 pg/mL, p = 0.002; interleukin-6: 67.50 vs 21.81 pg/mL, p = 0.005; and inte

19 Increases of interferon-gamma and interleukins 6, 7, and 8 occurred over time in patients

20 We determined that interleukins -6, -8, and -10 within the MCM are sufficie

21 xpression of human tumor necrosis factor and interleukin 6 (84% and 51% respectively; P < .01).

22 1 and a low abundance of the proinflammatory interleukin-6, a common risk factor for diabetes and met

23 Interleukin-6 acts as both a pro-inflammatory cytokine a

24 s, lower absolute levels of soluble CD14 and interleukin 6 and greater declines in the CD14 level and

25 ssociated among HIV-infected men with higher interleukin 6 and high-sensitivity C-reactive protein an

26 , resulting in expression of proinflammatory interleukin 6 and monocyte chemoattractant protein 1.

27 er levels of CRP, tumor necrosis factor, and interleukin 6 and shorter leukocyte telomere length.

28 nd downregulation of pro-oncogenic cytokines interleukin-6 and 8 (IL-6 and IL-8) as unexpected outcom

29 ry (im)balance by measuring pro-inflammatory interleukin-6 and anti-inflammatory interleukin-10 durin

30 enotype and confirm previous studies linking interleukin-6 and autism, suggesting potential novel the

31 ansfected with hHO-1 displayed an attenuated interleukin-6 and intercellular adhesion molecule 1 expr

32 We repeatedly measured plasma interleukin-6 and interleukin-10 concentrations using cy

33 e balance of this response as modelled by an interleukin-6 and interleukin-10 interaction term was no

34 Interleukin-6 and interleukin-10 levels were both indepe

35 fferences in interferon-gamma, CXCL12, XCL1, interleukin-6 and interleukin-10 levels.

36 Although both interleukin-6 and interleukin-10 productions are associa

37 induces NF-kappaB activation during DDR and interleukin-6 and interleukin-6 expression, both key NF-

38 h controls for the proinflammatory cytokines interleukin-6 and interleukin-8.

39 e tissue macrophage content, elevated plasma interleukin-6 and MCP-1 levels, and decreased skeletal m

40 ey injury markers (NGAL and KIM-1) and renal Interleukin-6 and Ngal mRNA observed 24 hours after admi

41 ative correlation with ex vivo production of interleukin-6 and tumor necrosis factor-alpha and a bord

42 LPS transiently increased interleukin-6 and tumor necrosis factor-alpha, sickness

43 nflammatory cytokines (interleukin-1beta and interleukin-6) and adenosine triphosphate were also meas

44 roducts (transforming growth factor beta and interleukin-6) and decreased the expression of inducible

45 ion (high-sensitivity C-reactive protein and interleukin-6), and there were modest increases in level

46 ft ventricular hypertrophy, glycemic traits, interleukin 6, and circulating lipids.

47 tory cytokines, including interleukin 1beta, interleukin 6, and interleukin 8, and marked inflammator

48 or necrosis factor alpha, interleukin 1beta, interleukin 6, and multiple chemokines/chemokine ligands

49 ains: "inflammation" (tumor necrosis factor, interleukin-6, and -10); "coagulation" (D-dimers, thromb

50 ukin-1beta, inducible nitric oxide synthase, interleukin-6, and gamma interferon in kidney tissue.

51 ike tyrosine kinase 3 ligand, interleukin-3, interleukin-6, and granulocyte colony-stimulating factor

52 or necrosis factor-alpha, interleukin-1beta, interleukin-6, and granulocyte macrophage colony-stimula

53 e expression of tumor necrosis factor alpha, interleukin-6, and interleukin-8 in the respiratory trac

54 looxygenase-2, C-C motif chemokine ligand 2, interleukin-6, and interleukin-8.

55 prostaglandin E2, epinephrine, TNFalpha, and interleukin-6, and the neuropathic pain induced by the c

56 on leads to the production of interleukin-2, interleukin-6, and transforming growth factor-beta, cyto

57 corticosterone, adrenocorticotropic hormone, interleukin-6, and tumor necrosis factor-alpha in mice e

58 iologic markers of inflammation such as CRP, interleukin-6, and tumor necrosis factor-alpha, and infl

59 tality for patients with different baseline [interleukin-6] and [interleukin-6] x [interleukin-10] pr

60 age inflammatory protein 1alpha/beta], IL-6 [interleukin 6], and IL-1beta [interleukin 1beta]), and m

61 GF], heparin-binding EGF-like growth factor, interleukin 6, angiopoietin, platelet-derived growth fac

62 interferon gamma, tumour necrosis factor and interleukin-6 are released by monocyte-derived macrophag

63 specific enolase: area under the curve=0.69; interleukin 6: area under the curve=0.82).

64 munication proteins such as immunomodulatory interleukin 6 as well as antioxidative and proproliferat

65 roduction of tumor necrosis factor alpha and interleukin 6, as measured by intracellular staining, wa

66 D5Rs (DRD5KO mice) to show that carrageenan, interleukin 6, as well as BDNF-induced hyperalgesia and

67 s, including tumor necrosis factor-alpha and interleukin-6 at baseline (rs = 0.39; p < 0.0001 and rs

68 At baseline, patients had much higher interleukin-6, C-reactive protein, and hepcidin levels.

69 Circadian misalignment increased 24-h serum interleukin-6, C-reactive protein, resistin, and tumor n

70 yed lower expression levels of the cytokines interleukin-6, chemokine ligand 2 and tumour necrosis fa

71 leukin 1beta (IL-1beta), interleukin 18, and interleukin 6; chemokines CCL2, CCL4, CCL11, CCL22, CXCL

72 The loss of JAK1 uncouples interleukin-6-class ligands from their downstream effect

73 esence of female genital cancer by comparing interleukin 6 concentration and microvesicle concentrati

74 Higher average maternal interleukin-6 concentration during pregnancy was prospec

75 ated the association between higher maternal interleukin-6 concentrations and lower impulse control.

76 soluble suppression of tumorigenicity-2 and interleukin-6 concentrations are each associated with wo

77 soluble suppression of tumorigenicity-2 and interleukin-6 concentrations had decreased probability o

78 Soluble suppression of tumorigenicity-2 and interleukin-6 concentrations have been associated with t

79 ntegrin-mediated adhesion to fibronectin and interleukin-6 confers a more malignant phenotype via amp

80 onse to lipopolysaccharide); increased serum interleukin 6, CXCL10, and interleukin 10 levels; increa

81 lonal antibody that selectively binds to the interleukin-6 cytokine with high affinity, is under deve

82 red levels of STAT3, P53, ligands for gp130, interleukin 6, cytokines, sonic hedgehog signaling, STAT

83 control mice, but this effect was delayed in interleukin 6-deficient mice.

84 al, and cardiometabolic factors, and CRP and interleukin-6, each standard deviation increase in sCD14

85 um, inducing tumor necrosis factor alpha and interleukin 6 expression, thus impairing L. monocytogene

86 s variable ventilation, 9 [8-10]; p < 0.01), interleukin-6 expression (volume-controlled ventilation,

87 n decreases in conjunction with increases in interleukin-6 expression and atherosclerosis severity.

88 showed that ferritin light chain, TLR4, and interleukin-6 expression were >100-fold higher in patien

89 activation during DDR and interleukin-6 and interleukin-6 expression, both key NF-kappaB target gene

90 reening was cardiotrophin-1, a member of the interleukin-6 family.

91 pond to LPS early, and interleukin-1beta and interleukin-6 fluctuated although they responded to trea

92 also had a significant reduction in level of interleukin 6 from baseline (decrease of 15%) compared w

93 io, 0.85; 95% CI, 0.72-1.00; p = 0.05; day 0 interleukin-6: hazard ratio, 0.64; 95% CI, 0.54-0.75; p

94 64; 95% CI, 0.54-0.75; p < 0.0001; and day 3 interleukin-6: hazard ratio, 0.73; 95% CI, 0.62-0.85; p

95 The following measurements were obtained: interleukin 6, high-sensitivity C-reactive protein, solu

96 crophage colony stimulating factor (GM-CSF), interleukin 6 (IL-6) among others, and stabilize and des

97 vity and significantly represses TNF-induced interleukin 6 (IL-6) and IL-8 mRNA expression and protei

98 creased c-Fos induced inflammatory cytokines interleukin 6 (IL-6) and tumor necrosis factor (TNF), le

99 4 at 7 days), and serum and tissue levels of interleukin 6 (IL-6) at 6 hours, hepatocyte growth facto

100 NS inflammatory responses as measured by CSF interleukin 6 (IL-6) concentration supports a role of ky

101 p130) is the common signal transducer of all interleukin 6 (IL-6) cytokines.

102 ological mechanical damage, via induction of interleukin 6 (IL-6) from epithelial cells, tailored eff

103 describe a new mouse strain, in which human interleukin 6 (IL-6) gene encoding the cytokine that is

104 Secretion of interleukin 6 (IL-6) in lipopolysaccharide-stimulated mo

105 ether ganciclovir prophylaxis reduces plasma interleukin 6 (IL-6) levels in CMV-seropositive adults w

106 e inflammatory response, cell proliferation, interleukin 6 (IL-6) levels, and intactness of vessels i

107 losis-specific adaptive immune responses and interleukin 6 (IL-6) levels, whereas controls with simil

108 ptical sensing platform on smartphone, human interleukin 6 (IL-6) protein and six types of plant viru

109 The cellular sources of interleukin 6 (IL-6) that are relevant for differentiati

110 ibodies to lipopolysaccharide (EndoCAb), and interleukin 6 (IL-6) were determined.

111 ines, keratinocyte chemoattractant (KC), and interleukin 6 (IL-6) were measured with enzyme-linked im

112 ding protein (I-FABP), soluble CD14 (sCD14), interleukin 6 (IL-6), and C-reactive protein (CRP) at 6

113 , adiponectin, C-reactive protein (CRP), and interleukin 6 (IL-6), as well as the homeostasis model a

114 Interleukin 6 (IL-6), high-sensitivity C-reactive protei

115 Multiple cytokines, including interleukin 6 (IL-6), IL-11, IL-27, oncostatin M (OSM),

116 ar interleukin 1alpha (IL-1alpha), IL-1beta, interleukin 6 (IL-6), interleukin 8, tumor necrosis fact

117 We evaluated plasma levels of autotaxin, interleukin 6 (IL-6), soluble CD14 (sCD14), soluble CD16

118 of proinflammatory immune mediators such as interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-a

119 ctor (TNF), interleukin 1beta (IL-1beta) and interleukin 6 (IL-6).

120 and activation, and that HCK is activated by interleukin 6 (IL-6).

121 ssive levels of the proinflammatory cytokine interleukin 6 (IL-6).

122 of matrix metalloproteases and synthesis of interleukin 6 (IL-6).

123 g plasma C-reactive protein (CRP, n = 4941), interleukin 6 (IL-6, n = 2859), and tumor necrosis facto

124 re, we report that the inflammatory cytokine interleukin-6 (IL-6) actively repressed Eos expression t

125 hat inflammation, and in particular elevated interleukin-6 (IL-6) activity, may be related to clinica

126 ), 15 studies including 3751 individuals for interleukin-6 (IL-6) and 10 studies including 881 indivi

127 pendent on exogenous soluble factors such as interleukin-6 (IL-6) and APRIL, to prevent their cell de

128 onstrate stability in detection of analytes, Interleukin-6 (IL-6) and Cortisol, from human sweat in R

129 systems, BMFs secreted high levels of murine interleukin-6 (IL-6) and hepatocyte growth factor (HGF),

130 naling mediator of many cytokines, including interleukin-6 (IL-6) and IL-10.

131 nd differentiate into GC Tfh cells following interleukin-6 (IL-6) and IL-21 stimulation, and viral DN

132 tive protein (CRP) and a panel of cytokines (interleukin-6 (IL-6) and tumor necrosis factor-alpha (TN

133 ation [fasting plasma C-reactive protein and interleukin-6 (IL-6) as primary endpoints] acutely and b

134 they were used for the selective capture of interleukin-6 (IL-6) as targeted antigen.

135 erclonal communication mechanism mediated by interleukin-6 (IL-6) cytokine secreted from EGFRvIII-pos

136 ilage explants, suppressing pro-inflammatory interleukin-6 (IL-6) expression after interleukin-1 beta

137 ing the release of the inflammatory cytokine interleukin-6 (IL-6) from human blood-derived dendritic

138 n of tumor necrosis factor alpha (TNF-alpha)/interleukin-6 (IL-6) in infected kidneys.

139 rs of inflammation and dominant producers of interleukin-6 (IL-6) in inflammatory diseases like rheum

140 tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in MRSA-infected skin lesions.

141 (NO), tumor necrosis factor (TNF)-alpha and interleukin-6 (IL-6) in the RAW264.7 macrophages stimula

142 used infiltration of the peripheral cytokine interleukin-6 (IL-6) into brain parenchyma and subsequen

143 Interleukin-6 (IL-6) is a biomarker of systemic inflamma

144 Interleukin-6 (IL-6) is a pro-carcinogenic inflammatory

145 ons of FITC-dextran gut translocation, serum interleukin-6 (IL-6) levels, bacteremia, and sepsis mort

146 PB interleukin-6 (IL-6) negatively correlated with endothel

147 ation factor, it is now known that mammalian interleukin-6 (IL-6) only regulates B cells committed to

148 se of keratinocyte-derived cytokine (KC) and interleukin-6 (IL-6) production by cells.

149 expression of the pro-inflammatory cytokine interleukin-6 (IL-6) relative to BALB/cJ and PDE11A WT m

150 In patients with chronic liver disease, interleukin-6 (IL-6) serum levels are elevated and incre

151 t2 selectively mediates active repression of interleukin-6 (IL-6) transcription during inflammation r

152 nduced elevation of circulating TNFalpha and interleukin-6 (IL-6) was abolished in TLR4(-/-) mice.

153 Interleukin-6 (IL-6) was identified as a regulator of mI

154 boratory stress paradigm on levels of plasma interleukin-6 (IL-6), a cytokine known to be both respon

155 factors, such as nerve growth factor (NGF), interleukin-6 (IL-6), and carrageenan, produce decreased

156 sion levels of gamma interferon (IFN-gamma), interleukin-6 (IL-6), and IL-1beta, accompanied by signi

157 ding inducible nitric oxide synthase (iNOS), interleukin-6 (IL-6), and IL-1beta.

158 cifically of STAT1 in response to IFN-gamma, interleukin-6 (IL-6), and IL-27.

159 le 1 (ICAM-1), interferon gamma (IFN-gamma), interleukin-6 (IL-6), and toll-like receptor 2 (TRL-2).

160 with assessment of C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor alpha (T

161 Levels of C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha an

162 ) receptor and the proinflammatory cytokine, interleukin-6 (IL-6), have both been implicated in psych

163 e secretion of gamma interferon (IFN-gamma), interleukin-6 (IL-6), interleukin-10 (IL-10), and comple

164 The inflammatory cytokine, interleukin-6 (IL-6), is a critical mediator of HCC deve

165 er levels of tumor necrosis factor (TNF) and interleukin-6 (IL-6), more neutrophil recruitment, and a

166 ted with increased spontaneous production of interleukin-6 (IL-6), suggesting an enhanced innate immu

167 Levels of two cytokines (interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-a

168 Interleukin-6 (IL-6)-activated Signal Transducer and Act

169 Genes associated with MDD were enriched for interleukin-6 (IL-6)-signaling and natural killer (NK) c

170 )-mediated insulin secretion by upregulating interleukin-6 (IL-6).

171 an array of immunological proteins, such as interleukin-6 (IL-6).

172 duction of the plasma cell survival cytokine interleukin-6 (IL-6).

173 as quantitative PCR was performed to measure interleukin-6 (IL-6, a pro-inflammatory marker implicate

174 Hypoxia and inflammatory cytokines like interleukin-6 (IL-6, IL6) are strongly linked to cancer

175 red parasite biomass, systemic inflammation (interleukin 6 [IL-6]), endothelial activation (angiopoie

176 in, tumor necrosis factor alpha [TNF-alpha], interleukin 6 [IL-6], and soluble CD14) and interleukin

177 nes/chemokines (tumor necrosis factor alpha, interleukin 6 [IL-6], IL-8, interferon gamma-induced pro

178 pondin 2; intercellular adhesion molecule 1; interleukin 6 [IL-6]; stromal cell-derived factor 1; tis

179 tem elicit higher levels of cytokines (e.g., interleukin-6 [IL-6]) following infection of U937 cells,

180 es (tumor necrosis factor alpha [TNF-alpha], interleukin-6 [IL-6], and IL-12), anti-inflammatory cyto

181 macrophage colony-stimulating factor [MCSF], interleukin-6 [IL-6], IL-8, IL-1alpha, CXCL1, CXCL2, CXC

182 se 1 [HO-1]), and proinflammatory cytokines (interleukin-6 [IL-6], IL-8, monocyte chemoattractant pro

183 rates of TB recurrence in univariate models: interleukin 6 (IL6) (odds ratio [OR] 2.66, 95% confidenc

184 notropic peptide (GIP) induces production of interleukin 6 (IL6) by adipocytes.

185 We found that interleukin 6 (IL6) derived mainly from cancer-associate

186 re; Egfr(f/f) mice had reduced expression of interleukin 6 (IL6), and epithelial STAT3 activation was

187 ion of cells also blocked signaling by IFNB, interleukin 6 (IL6), and IL22 and reduced activation of

188 a-ketoglutarate dependent dioxygenase (FTO), interleukin 6 (IL6), insulin receptor (INSR), neuronal g

189 C-C motif chemokine ligand 2 (CCL2), interleukin 6 (IL6), tumor necrosis factor (TNF), and ni

190 is associated with poor survival in HCC and interleukin-6 (IL6) expression.

191 in the bone microenvironment by stimulating interleukin-6 (IL6) release from osteoblasts, and trigge

192 icant enrichment for genes known to regulate interleukin-6 (IL6) signaling, cell adhesion, and angiog

193 perioperative pharmacological inhibition of interleukin-6 (IL6), which is a crucial liver regenerati

194 y fat, percent trunk fat, and serum level of interleukin 6 in children with overweight or obesity.

195 al role for tumour necrosis factor alpha and interleukin 6 in disease pathogenesis and possibly also

196 Increased concentrations of aromatase and interleukin 6 in inflamed breast tissue and an increased

197 e major immune cell populations that produce interleukin-6 in middle-aged mice during systemic inflam

198 veness of biological therapies, such as anti-interleukin 6, in patients with polymyalgia rheumatica t

199 idine triphosphate nucleotidohydrolase in an interleukin 6-independent manner.

200 (IFNgamma), interleukin1beta, interleukin 2, interleukin 6, interleukin 10 (IL-10), and soluble CD14

201 Interleukin 6, interleukin 10 receptor alpha subunit, co

202 ed SAMHD1 and proinflammatory cytokines (eg, interleukin 6, interleukin 1beta, and tumor necrosis fac

203 e growth factor-1, B-cell activating factor, interleukin-6, interleukin-10).

204 r genetic ablation of pericentrin attenuated interleukin-6, interleukin-10, and MCP1 secretion, sugge

205 tive catalase; and 3) selective secretion of interleukin-6, interleukin-10, and vascular endothelial

206 of proinflammatory cytokines (interleukin-3, interleukin-6, interleukin-13, interleukin-17, macrophag

207 and expression of proinflammatory mediators interleukin-6, interleukin-1beta, and CXCL1/2 (C-X-C mot

208 served a significant and massive increase of interleukin-6, interleukin-1beta, and tumor necrosis fac

209 In addition, we measured changes in interleukin-6, interleukin-8, and interleukin-10 blood l

210 al injury (angiopoietin-2) and inflammation (interleukin-6, interleukin-8, and interleukin-33 and sol

211 at principal component 1, mainly loaded with interleukin-6, interleukin-8, interleukin-10, and fracta

212 A group consisting of interleukin-6, interleukin-8, interleukin-10, and fracta

213 Interleukin-6, interleukin-8, interleukin-10, interleuki

214 Levels of tissue necrosis factor, interleukin-6, interleukin-8, interleukin-17A, and inter

215 ducts, surfactant protein D, angiopoietin-2, interleukin-6, interleukin-8, interleukin-33, and solubl

216 er N-acetyl-l-cysteine reduced the levels of interleukin-6, interleukin-8/C-X-C motif chemokine ligan

217 interleukin-2, interleukin-4, interleukin-5, interleukin-6, interleukin-9, interleukin-10, interleuki

218 The interleukin-6/interleukin-10 ratio directly correlated w

219 Interleukin-6 is a cytokine critical to proinflammatory

220 erformed studies with C57Bl6-J (control) and interleukin 6-knockout mice.

221 aHR], 2.74), soluble CD14 level (aHR, 2.32), interleukin 6 level (aHR, 2.34), and D-dimer level (aHR,

222 soluble suppression of tumorigenicity-2 and interleukin-6 levels can be used as prognostic biomarker

223 well as a 77% reduction (p < 0.05) in serum interleukin-6 levels compared to matched controls.

224 soluble suppression of tumorigenicity-2 and interleukin-6 levels were associated with duration of me

225 This was accompanied with reduced serum interleukin-6 levels.

226 able to increase synaptogenesis by blocking interleukin-6 levels.

227 se in circulating pro-inflammatory cytokine (interleukin-6) levels 3 h after injection, indicating in

228 ted by Drosophila tumour necrosis factor and interleukin-6-like signalling from metabolically stresse

229 induced expression of interleukin 1beta and interleukin 6 messenger RNAs in mouse bone marrow-derive

230 tary restriction and correlated with adipose interleukin-6 messenger RNA levels and fat mass (p < 0.0

231 d with serum levels of C-reactive protein or interleukin-6; miR-1180 was associated with pulmonary fu

232 Lower levels of interleukin-6, monocyte chemotactic protein-1 (MCP-1), a

233 umorigenicity-2 (n = 826) concentrations and interleukin-6 (n = 755) concentrations in the Fluid and

234 3.23; 95% CI, 1.04-10.07; p = 0.04) and for interleukin-6 (odds ratio, 2.58; 95% CI, 1.14-5.84; p =

235 atio, 0.62: 95% CI, 0.44-0.87; p = 0.006 and interleukin-6: odds ratio, 0.61; 95% CI, 0.43-0.85; p =

236 in concentrations of hsCRP of 26-41% and of interleukin 6 of 25-43% (p<0.0001 for all comparisons).

237 scence-associated secretory phenotype factor interleukin-6 orchestrates both increases in suppressive

238 lycolysis and an altered cytokine secretion (interleukin-6 P<0.0001, interleukin-8/C-X-C motif chemok

239 40 with eritoran in reducing E. coli-induced interleukin 6 (P < .05) and monocyte activation markers

240 ripheral blood mononuclear cells and reduced interleukin 6 (P = .028) and GVHD biomarkers (Reg3, P =

241 predictors of cognitive impairment, whereas interleukin-6 (P = 0.019) demonstrated cognitive protect

242 ated tumor necrosis factor-alpha, p = 0.003; interleukin-6, p = 0.01; interleukin-10, p = 0.005), and

243 tic livers of beta2SP(+/-) mice treated with interleukin-6 (pIL6; (IL6) beta2SP(+/-) LSCs) were highl

244 Interleukin 6 plays a key role in mediating inflammatory

245 , midregional proadrenomedullin, cystatin-C, interleukin-6, procalcitonin, and others.

246 or necrosis factor alpha, interleukin 10, or interleukin 6 production by HBV surface antigen-specific

247 logical outcomes of infection by suppressing interleukin 6 production in the brain.

248 ce causes extensive pathophysiology owing to interleukin 6 production.

249 ostburn hepatic damage through p38-dependent interleukin-6 production in Kupffer cells.

250 yme of the shunt, inhibited nitric oxide and interleukin-6 production in M1 macrophages, while promot

251 cible corticosteroid specifically suppresses interleukin-6 production without affecting tumor necrosi

252 CA inhibited interferon-gamma and stimulated interleukin-6 production, each of which was antagonized

253 ter injury and analyzed for p38 activity and interleukin-6 production.

254 corresponded to a 43% (p < 0.05) increase in interleukin-6 production.

255 on in vivo, which is a result of a defect of interleukin-6 production.

256 Interleukin 6 protects pancreatic beta cells from apopto

257 , interleukin-10 (r = -0.59, P = 0.007), and interleukin-6 (r = -0.54, P = 0.01).Urinary alpha-CEHC a

258 active protein [CRP], interleukin 6, soluble interleukin 6 receptor [sIL-6R], soluble gp130, tumor ne

259 The efficacy and safety of tocilizumab, an interleukin 6 receptor-alpha inhibitor, was assessed in

260 es to map integratively the epitope of human interleukin-6 receptor (IL-6R) for two adnectins with di

261 The Asp358Ala variant in the interleukin-6 receptor (IL-6R) gene has been implicated

262 pecifically cleaved by RHBDL2, including the interleukin-6 receptor (IL6R), cell surface protease inh

263 -1 receptor antagonist (IL-1Ra), and soluble interleukin-6 receptor (sIL-6R).

264 te that the proportion of CD5(+) relative to interleukin-6 receptor alpha (IL-6Ralpha)-expressing B c

265 The effect of the interleukin-6 receptor alpha inhibitor tocilizumab on th

266 iovascular dysfunction were treated with the interleukin-6 receptor antibody tocilizumab.

267 Interleukin-6 receptor blockade with tocilizumab remains

268 Functional variants in the interleukin-6 receptor gene (IL6R) are associated with a

269 on to baseline levels through suppression of interleukin-6 receptor signaling.

270 cacy and safety of strategies initiating the interleukin-6 receptor-blocking monoclonal antibody toci

271 rotein S[rs6123] in the schizophrenia group; Interleukin-6 receptor[rs7553796] in both the control an

272 uated glutamate uptake, intramyelinic edema, interleukin-6 release, complement activation, inflammato

273 AQP4 within the plasma membrane and induces interleukin-6 release.

274 and TLR7/8 stimulation (P = .035), a reduced interleukin 6 response to TLR7/8 stimulation (P = .037),

275 restricted mice showed significantly reduced interleukin-6 secretion compared with that from freely f

276 Furthermore, after identifying interleukin-6 secretion from astrocytes in individuals w

277 4 and nuclear factor-kappaB (NF-kappaB)- and interleukin-6/signal transducer and activator of transcr

278 Interleukin-6 significantly correlated with alveolar bon

279 Interleukin 6 (SMD 0.88; p=0.0003), interleukin 1beta (S

280 s of inflammation (C-reactive protein [CRP], interleukin 6, soluble interleukin 6 receptor [sIL-6R],

281 igher AT1RaAbs correlated significantly with interleukin-6 (Spearman r=0.33, P<0.0001), systolic bloo

282 , which is consistent with a synergy between interleukin 6/STAT3 and BMP/SMAD signaling in regulating

283 so effectively inhibits the constitutive and interleukin-6-stimulated expression of STAT3 downstream

284 t is more effective at promoting TLR-induced interleukin-6 than the non-risk Lyp620R protein.

285 ological indicator of maternal inflammation (interleukin-6) that has been shown to influence fetal br

286 otoxic chemotherapy (47/128 [37%]), and anti-interleukin 6 therapy (11/128 [9%]).

287 eral fat-derived messenger RNA expression of interleukin-6, thrombospondin-1, plasminogen activator i

288 actor-alpha, interleukin-1beta) and restored interleukin-6 to control levels in the renal cortex, ind

289 increase in CSF levels of interleukin-1beta, interleukin-6, tumor necrosis factor alpha, interleukin-

290 ansduction and activator of transcription 3, interleukin-6, tumor necrosis factor, and forkhead box P

291 nnate immune system (% CD16+CD14+ monocytes, interleukin-6, tumour necrosis factor-a and colony-stimu

292 tio, 0.45; 95% CI, 0.28-0.71; p = 0.0007 and interleukin-6 univariate analysis only: odds ratio, 0.55

293 for the detection of the inflammatory marker interleukin 6 via a sandwich immunoassay.

294 gene expression for the major latency, viral interleukin 6 (vIL-6), and vIRF3 transcripts.

295 Viral interleukin-6 (vIL-6) encoded by human herpesvirus 8 (HH

296 Interleukin 6 was reduced following PVI treatment.

297 fect of the experimental treatments on adult interleukin-6 was partially mediated by increased juveni

298 Plasma levels of interleukin-6 were significantly reduced by dietary rest

299 ion, high-sensitivity C-reactive protein and interleukin-6, when the birds were adults.

300 with different baseline [interleukin-6] and [interleukin-6] x [interleukin-10] profiles, whereas pati